Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD01190 ...
Drug Name Clindamycin
Molecular Weight 424.983
Molecular Formula C18H33ClN2O5S
CAS Number 18323-44-9
SMILES CCC[C@@H]1C[C@H](N(C)C1)C(=O)NC(C(C)Cl)[C@H]1O[C@H](SC)[C@H](O)[C@@H](O)[C@H]1O
External Links
DRUGBANK DB01190
T3DB T3D3497
PubChem Compound 446598
PDR 1019
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 2.16 - 2.16 - HANSCH,C ET AL. (1995)
Melting Point 141.0 ℃ 141-143 ℃ Canadian labeling
pKa 7.6 - 7.6 - Canadian labeling

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
AUC 11000.0 ng.h/ml 11.0 ug.h/ml Oral single dose; DRUGBANK
Bioavailability 90.0 % ~90 % PO, oral; DRUGBANK
Bioavailability 87.0 % ~87 % PO, oral; The Pharmacological Basis of Therapeutics
C Max 2500.0 ng/ml 2.5 ug/ml PO, oral; DRUGBANK
C Max 17200.0 ng/ml 17.2±3.5 mcg/ml intravenous injection, IV; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 2500.0 ng/ml 2.5 mcg/ml PO, oral; adults; The Pharmacological Basis of Therapeutics
T Max 0.75 h 0.75 h PO, oral; DRUGBANK
Clearance 14.9 L/h 12.3-17.4 L/h Plasma clearance; Hepatitis, Hep ↓ ; DRUGBANK
Clearance 0.28 L/h/kg 4.7±1.3 ml/min/kg Children → ; The Pharmacological Basis of Therapeutics
Clearance 0.27 L/h/kg 4.5 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 58.5 L 43-74 L DRUGBANK
Volume of Distribution 1.1 L/kg 1.1±0.3 L/kg Children → ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.79 L/kg 0.79 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 3.0 h ~3 h adults; DRUGBANK
Half-life 2.5 h 2.5 h Children; DRUGBANK
Half-life 4.0 h ~4 h Elderly; DRUGBANK
Half-life 2.9 h 2.9±0.7 h Children → ;Preg, pregnant → ;Prem, premature ↑ ;RD, renal impairment, Renal disease，including uremia → ; The Pharmacological Basis of Therapeutics
Half-life 2.1 h 2.1 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 2540.0 mg/kg 2540.0 mg/kg PO, oral; mouse; DRUGBANK
Toxicity LD50 2190.0 mg/kg 2190.0 mg/kg PO, oral; Rattus, Rat; DRUGBANK
Eliminate Route 13.0 % 13 % Urinary excretion; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 77.0 % 60-94 % DRUGBANK
Protein Binding 93.6 % 93.6±0.2 % The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for neonates 20.0 mg/kg/day 20 mg/kg/day intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for neonates 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for neonates 27.0 mg/kg/day 9 mg/kg/dose PO, oral;intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for neonates 21.0 mg/kg/day 7 mg/kg/dose PO, oral;intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for neonates 15.0 mg/kg/day 5 mg/kg/dose PO, oral;intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for infants 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for infants 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for infants 40.0 mg/kg/day 40 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for children 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for children 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for children 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 40.0 mg/kg/day 40 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 2.0 application/day 2 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for children 1.0 application/day 1 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for children 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for children 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for children 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for children 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 40.0 mg/kg/day 40 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for children 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for adolescents 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 40.0 mg/kg/day 40 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2.0 application/day 2 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 applicatorful/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 applicatorful/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 ovule/day 1 ovule/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 40.0 mg/kg/day 40 mg/kg/day intravenous injection, IV;IM,intramuscular injection; Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for adolescents 25.0 mg/kg/day 25 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 40.0 mg/kg/day 40 mg/kg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adolescents 2.0 application/day 2 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 applicatorful/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 application/day 1 applicatorful/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 1.0 ovule/day 1 ovule/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adolescents 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for adults 4800.0 mg/day 4800 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for adults 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for adults 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for adults 2.0 appLication/day 2 appLication/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adults 1.0 appLication/day 1 appLication/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for adults 1.0 appLicatorfuL/day 1 appLicatorfuL/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 1.0 appLicatorfuL/day 1 appLicatorfuL/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 1.0 ovuLe/day 1 ovuLe/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for adults 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 2700.0 mg/day 2700 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for geriatric 4800.0 mg/day 4800 mg/day intravenous injection, IV Cleocin T clindamycin phosphate PDR
Max dose for geriatric 2400.0 mg/day 2400 mg/day IM,intramuscular injection Cleocin T clindamycin phosphate PDR
Max dose for geriatric 1800.0 mg/day 1800 mg/day PO, oral Cleocin T clindamycin phosphate PDR
Max dose for geriatric 2.0 application/day 2 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for geriatric 1.0 application/day 1 application/day skin/dermal Cleocin T clindamycin phosphate PDR
Max dose for geriatric 1.0 applicatorful/day 1 applicatorful/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 1.0 applicatorful/day 1 applicatorful/day Vaginal Administration; once Cleocin T clindamycin phosphate PDR
Max dose for geriatric 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 5000.0 mg/day 5 g/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 1.0 ovule/day 1 ovule/day Vaginal Administration Cleocin T clindamycin phosphate PDR
Max dose for geriatric 100.0 mg/day 100 mg/day Vaginal Administration Cleocin T clindamycin phosphate PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1